New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia - Current Treatment Options in Oncology
Source : https://link.springer.com/article/10.1007/s11864-022-00974-0
The better understanding of the biology of chronic lymphocytic leukemia (CLL) gained over the past decade has led to the development and introduction of several targeted drugs, with an demonstrable...
Conclusion/Relevance: Currently, Bruton's tyrosine kinase (BTK) inhibitors, phosphoinositide 3-kinase (PI3K) inhibitors, venetoclax, and CD20 monoclonal antibodies are the key elements in the treatment of both previously untreated and relapsed/refractory CLL patients.
A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35383885/
This single-arm, multicentre, phase I study is the first study of zanubrutinib, a potent, specific, irreversible Bruton tyrosine kinase (BTK) inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies. The objectives...
Conclusion/Relevance: Overall, zanubrutinib was well tolerated and either of these two regimens is clinically practical.
Harnessing Mitochondrial Mutations to ATAC Clonal Evolution in CLL - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35363869/
In this issue of Cancer Discovery, Penter and colleagues describe the results of applying the recently described technology of combined assay for transposase-accessible chromatin using sequencing and mitochondrial DNA sequencing...
Conclusion/Relevance: The naturally occurring barcodes, provided by mitochondrial DNA mutations, allowed tracking of subclones with distinct chromatin accessibility profiles and copy-number alterations demonstrating distinct patterns of tumor evolution under a range of selection pressures.
Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35349631/
In chronic lymphocytic leukemia (CLL) patients who achieve a complete remission (CR) to anti-CD19 chimeric antigen receptor T cells (CART-19), remissions are remarkably durable. Preclinical data suggesting synergy between CART-19...
Conclusion/Relevance: Preclinical data suggesting synergy between CART-19 and the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib prompted us to conduct a prospective single-center phase 2 trial in which we added autologous anti-CD19 humanized binding domain T cells (huCART-19) to ibrutinib in CLL patients not in CR despite at least 6 months...
An open-label, phase 1, randomized, three treatments, three-period, crossover, relative bioavailability study of CC-292, a potent and orally available inhibitor of bruton tyrosine kinase - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35307850/
For all three formulations, following administration of CC-292 at a dose level of 250 mg under fasted conditions, CC-292 was rapidly absorbed with maximum plasma concentrations (Cmax) occurring at a...
Relevance: The aim of this study was to evaluate the relative bioavailability of newly developed CC-292 tablet formulation (P22 tablet (P22-TAB) and CC-292 capsule formulation (P22 capsule [P22-CAP]) compared to the current CC-292 capsule formulation (P1 capsule [P01-CAP]).